Reuters logo
BRIEF-Gensight Biologics reports positive update in phase I/II GS010 study
December 20, 2016 / 6:33 AM / a year ago

BRIEF-Gensight Biologics reports positive update in phase I/II GS010 study

Dec 20 (Reuters) - Gensight Biologics SA :

* Gensight biologics reports sustained visual acuity gain at 78 weeks in its phase I/II study with gs010 for the treatment of leber’s hereditary optic neuropathy (LHON)

* Sustained improvement of visual acuity in patients with vision loss for less than 2 years

* Confirmation of good safety and tolerability profile of GS010 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below